Nephros, Inc. NEPH 深 沪
等待开盘 04-02 09:30:00 美东时间
2.96
-0.020
-0.67%
华盛通- 最 高2.98
- 今 开2.98
- 成交量 2.03万股
- 最 低 2.80
- 昨 收 2.98
- 总市值 3150.70万
- 52周最高 6.42
- 市盈率 静 27.18
- 换手率 0.19%
- 52周最低 1.64
- 委 比 67.05%
- 总股本 1064.43万
- 历史最高 11.666
- 量 比 1.38
- 振 幅 6.04%
- 历史最低 0.905
- 每 手 1
- 风险率 1.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Industrials Stocks Moving In Monday's Intraday Session
Gainers Distribution Solns Group (NASDAQ:DSGR) shares increased by 33.1% to $2...
03-17 01:05
电话会总结 ｜ Nephros(NEPH)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Nephros业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年全年营收1,880万美元，同比增长33% - 第四季度营收470万美元，同比增长22% - 营收增长主要由程序化销售、服务收入和应急响应业务驱动 **盈利能力：** - 2025年净利润120万美元，较上年的10万美元大幅增长 - 连续第二年实现盈利，为公司历史上仅有的两个盈利年份 - 全年毛利率维持62%不变，但第四季度毛利率从64%下降至58% **现金流状况：** - 经营活动现金流入160万美元，上年为流出50万美元 - 年末现金余
03-16 14:24
Nephros Q4 EPS $0.01, Inline, Sales $4.729M Beat $4.451M Estimate
Nephros (NASDAQ:NEPH) reported quarterly earnings of $0.01 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.03 per share from the same period last year. The
03-13 04:14
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Nephros and Medica Sign New Exclusive License And Supply Agreement; Company Has Agreed To Make Minimum Annual Aggregate Purchases From Medica Of €4,976,000, €5,349,000, €5,750,000, €6,000,000 And €6,300,000 For The Years 2026, 2027, 2028, 2029 And 2030, Respectively
On November 21, 2025, Nephros, Inc. (the "Company") entered into a license and supply agreement (the "License and Supply Agreement") with Medica S.p.A. ("Medica"), an Italy-based medical product manufacturing company,
2025-11-27 05:20
¬Nephros Schedules Third Quarter 2025 Financial Results Conference Call
*Nephros, Inc. announces it will release third-quarter financial results on November 6, 2025, after market close and host a conference call at 4:30pm ET. Participants can join via domestic access: 1 (844) 808-7106 or international access: 1 (412) 317-5285, and ask to be connected to the Nephros conference. An audio archive will be available on the Nephros Investor Relations page shortly after the call and replay available until November 13, 2025,...
2025-10-30 20:00
Nephros Launches New PFAS Filter for Point-of-Use Protection of Potable Water
Nephros, Inc. has launched its new 19-Series PFAS Filter, designed to reduce Total PFAS in drinking water. Unlike most filters that target only PFOA and PFOS, this product addresses a broader range of PFAS contaminants, which are persistent and harmful to human health. The filter also removes other hazardous substances such as lead and asbestos, offering comprehensive protection. Key features include NSF certification, high capacity, and suitabil...
2025-10-08 13:00
美股大行评级 | 潜在涨幅286.44%！RBC Capital上调Edgewise Therapeutics目标价至49美元，维持"跑赢大市"评级
今日重点评级关注：RBC Capital：维持Edgewise Therapeutics"跑赢大市"评级，目标价从48美元升至49美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从6美元升至7美元
2025-08-11 09:43
Maxim Group Maintains Buy on Nephros, Raises Price Target to $6
Maxim Group analyst Anthony Vendetti maintains Nephros (NASDAQ:NEPH) with a Buy and raises the price target from $4.5 to $6.
2025-08-09 06:58
Nephros shares are trading higher after the company reported better-than-expected Q2 financial results.
Nephros shares are trading higher after the company reported better-than-expect...
2025-08-08 20:58
